Differential bidirectional transfer of indinavir in the isolated perfused human placenta

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 1023-1028

  Sudhakaran, Sreeja ^a   Ghabrial, Hany ^b   Nation, Roger L ^a   Kong, David C M ^a,c   Gude, Neil M ^d   Angus, Peter W ^b   Rayner, Craig R ^a  

^a MONASH UNIVERSITY   (Australia)

^b AUSTIN HEALTH   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; INDINAVIR; PHENAZONE; VINBLASTINE;

ARTICLE; DIFFUSION; DRUG ABSORPTION; DRUG CLEARANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIQUID SCINTILLATION COUNTING; PLACENTA; PREGNANCY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STEADY STATE;

BIOLOGICAL TRANSPORT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MATERNAL-FETAL EXCHANGE; PERFUSION; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 14744269784     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.1023-1028.2005     Document Type: Article

References (37)

1. Andersen, P. L., R. C. Brundage, L. Bushman, T. N. Kakuda, R. P. Remmel, and C. V. Fletcher. 2000. Indinavir plasma protein binding in HIV-1-infected adults. AIDS 14:2293-2297.
2. Atkinson, D., S. Greenwood, C. Sibley, J. Glazier, and L. Fairbairn. 2003. Role of MDR1 and MRP1 in trophoblast cells; elucidated using retroviral gene transfer. Am. J. Physiol. Cell Physiol. 285:C584-C591.
3. Back, D. J., S. H. Khoo, S. E. Gibbons, and C. Merry. 2001. The role of therapeutic drug monitoring in treatment of HIV infection. Br. J. Clin. Pharmacol. 51:301-308.
4. Bawdon, R. E. 1998. The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir. Infect. Dis. Obstet. Gynecol. 6:244-246.
5. Bourget, P., C. Roulot, and H. Fernandez. 1995. Models for placental transfer studies of drugs. Clin. Pharmacokinet. 28:161-180.
6. Casey, B. M., and R. E. Bawdon. 1998. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am. J. Obstet. Gynecol. 179:758-761.
7. Ching, M. S., M. A. Czuba, G. W. Mihaly, D. J. Morgan, K. M. Hyman, J. D. Paull, and R. A. Smallwood. 1988. Mechanism of triamterene transfer across the human placenta. J. Pharmacol. Exp. Ther. 246:1093-1097.
8. Ching, M. S., G. W. Mihaly, D. J. Morgan, N. M. Date, K. J. Hardy, and R. A. Smallwood. 1987. Low clearance of cimetidine across the human placenta. J. Pharmacol. Exp. Ther. 241:1006-1009.
9. Cooper, E. R., M. Charurat, L. Mofenson, I. C. Hanson, J. Pitt, C. Diaz, K. Hayani, E. Handelsman, V. Smeriglio, R. Hoff, W. Blattner, et al. 2002. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 29:484-494.
10. Csajka, C., C. Marzolini, K. Fattinger, L. A. Decosterd, A. Telenti, J. Biollaz, and T. Buclin. 2004. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 48:3226-3232.
11. Forestier, F., P. de Renty, G. Peytavin, E. Dohin, R. Farinotti, and L. Mandelbrot. 2001. Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am. J. Obstet. Gynecol. 185:178-181.
12. Garcia, P. M., L. A. Kalish, J. Pitt, H. Minkoff, T. C. Quinn, S. K. Burchett, J. Kornegay, B. Jackson, J. Moye, C. Hanson, C. Zorrilla, and J. F. Lew. 1999. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N. Engl. J. Med. 341:394-402.
13. Ghabrial, H., M. A. Czuba, C. K. Stead, R. A. Smallwood, and D. J. Morgan. 1991. Transfer of acipimox across the isolated perfused human placenta. Placenta 12:653-661.
14. Gutmann, H., G. Fricker, J. Drewe, M. Toeroek, and D. S. Miller. 1999. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol. 56:383-389.
15. Huisman, M. T., J. W. Smit, and A. H. Schinkel. 2000. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 14:237-242.
16. Ioannidis, J. P., E. J. Abrams, A. Ammann, M. Bulterys, J. J. Goedert, L. Gray, B. T. Korber, M. J. Mayaux, L. M. Mofenson, M. L. Newell, D. E. Shapiro, J. P. Teglas, and C. M. Wilfert. 2001. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J. Infect. Dis. 183:539-545.
17. Joint United Nations Program on HIV/AIDS and World Health Organization. 2002. AIDS epidemic update, December 2002. [Online.] http://www.unaids.org/ wad2004/EPI_1204_pdf_en/EpiUpdate04_en.pdf.
18. Lallemant, M., G. Jourdain, S. Le Coeur, S. Kim, S. Koetsawang, A. M. Comeau, W. Phoolcharoen, M. Essex, K. McIntosh, and V. Vithayasai. 2000. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N. Engl. J. Med. 343:982-991.
19. Lee, C. G., M. M. Gottesman, C. O. Cardarelli, M. Ramachandra, K. T. Jeang, S. V. Ambudkar, I. Pastan, and S. Dey. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
20. Lin, J. H., and M. Yamazaki. 2003. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42:59-98.
21. Marzolini, C., C. Rudin, L. A. Decosterd, A. Telenti, A. Schreyer, J. Biollaz, T. Buclin, and the Swiss Mother + Child HIV Cohort Study. 2002. Transplacental passage of protease inhibitors at delivery. AIDS 16:889-893.
22. Merck & Co. 1999. Crixivan (indinavir sulphate) product information. Merck & Co., Inc., Rahway, N.J.
23. Mirochnick, M., A. Dorenbaum, D. Holland, B. Cunningham-Schrader, C. Cunningham, R. Gelber, L. Mofenson, M. Culnane, J. Connor, and J. L. Sullivan. 2002. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr. Infect. Dis. J. 21:835-838.
24. Mofenson, L. M., Centers for Disease Control and Prevention, and U.S. Public Health Service Task Force. 2002. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Morb. Mortal. Wkly. Rep. 51(RR-18):1-38; quiz CE1-4.
25. Molla, A., G. R. Granneman, E. Sun, and D. J. Kempf. 1998. Recent developments in HIV protease inhibitor therapy. Antivir. Res. 39:1-23.
26. Morris, A. B., S. Cu-Uvin, J. I. Harwell, J. Garb, C. Zorrilla, M. Vajaranant, A. R. Dobles, T. B. Jones, S. Carlan, and D. Y. Allen. 2000. Multicenter review of protease inhibitors in 89 pregnancies. J. Acquir. Immune Defic. Syndr. 25:306-311.
27. Pacifici, G. M., and R. Nottoli. 1995. Placental transfer of drugs administered to the mother. Clin. Pharmacokinet. 28:235-269.
28. Pasanen, M. 1999. The expression and regulation of drug metabolism in human placenta. Adv. Drug Deliv. Rev. 38:81-97.
29. Peckham, C., and D. Gibb. 1995. Mother-to-child transmission of the human immunodeficiency virus. N. Engl. J. Med. 333:298-302.
30. Penfold, P., L. Drury, R. Simmonds, and F. E. Hytten. 1981. Studies of a single placental cotyledon in vitro. I. The preparation and its viability. Placenta 2:149-154.
31. Perloff, M. D., L. L. von Moltke, J. M. Fahey, J. P. Daily, and D. J. Greenblatt. 2000. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 14:1287-1289.
32. Rayner, C. R., L. D. Esch, H. E. Wynn, and R. Eales. 2001. Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen. Ann. Pharmacother. 35:1391-1395.
33. Schneider, H., M. Panigel, and J. Dancis. 1972. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am. J. Obstet. Gynecol. 114:822-828.
34. Smit, J. W., M. T. Huisman, O. van Tellingen, H. R. Wiltshire, and A. H. Schinkel. 1999. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Investig. 104:1441-1447.
35. Srinivas, R. V., D. Middlemas, P. Flynn, and A. Fridland. 1998. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob. Agents Chemother. 42:3157-3162.
36. Ushigome, F., H. Takanaga, H. Matsuo, S. Yanai, K. Tsukimori, H. Nakano, T. Uchiumi, T. Nakamura, M. Kuwano, H. Ohtani, and Y. Sawada. 2000. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur. J. Pharmacol. 408:1-10.
37. Young, A. M., C. E. Allen, and K. L. Audus. 2003. Efflux transporters of the human placenta. Adv. Drug Deliv. Rev. 55:125-132.